Tianjin Medical University Cancer Institute and Hospital is the birthplace of oncology in China. It has developed into one of the largest cancer centers in China.

During the past decade, Tianjin Medical University Cancer Institute and Hospital conducted 417 clinical trials. In the 10-year time frame, 417 clinical trials started and 36 clinical trials were completed, i.e. on average, 8.6% percent of trials that started reached the finish line to date. In the past 5 years, 283 clinical trials started and 25 clinical trials were completed. i.e. 8.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tianjin Medical University Cancer Institute and Hospital" #1 sponsor was "Tianjin Medical University Cancer Institute and Hospital" with 131 trials, followed by "Hoffmann-La Roche" with 43 trials sponsored, "BeiGene" with 31 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 29 trials sponsored and "Janssen Research & Development, LLC" with 29 trials sponsored. Other sponsors include 230 different institutions and companies that sponsored additional 127 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tianjin Medical University Cancer Institute and Hospital" #1 collaborator was "Tianjin Medical University Cancer Institute and Hospital" with 17 trials as a collaborator, "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 10 trials as a collaborator, "Peking University Cancer Hospital & Institute" with 10 trials as a collaborator, "Fudan University" with 8 trials as a collaborator and "Eli Lilly and Company" with 7 trials as a collaborator. Other collaborators include 319 different institutions and companies that were collaborators in the rest 208 trials.

According to Clinical.Site data, the most researched conditions in "Tianjin Medical University Cancer Institute and Hospital" are "Breast Cancer" (35 trials), "Gastric Cancer" (26 trials), "Non-small Cell Lung Cancer" (18 trials), "Non-Small Cell Lung Cancer" (13 trials) and "Non Small Cell Lung Cancer" (12 trials). Many other conditions were trialed in "Tianjin Medical University Cancer Institute and Hospital" in a lesser frequency.

Most popular intervention types in "Tianjin Medical University Cancer Institute and Hospital" are "Drug" (419 trials), "Biological" (32 trials), "Other" (27 trials), "Procedure" (22 trials) and "Radiation" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (48 trials), "Atezolizumab" (21 trials), "Tislelizumab" (21 trials), "Anlotinib" (20 trials) and "Cisplatin" (20 trials). Other intervention names were less common.

The vast majority of trials in "Tianjin Medical University Cancer Institute and Hospital" are 430 trials for "All" genders, 45 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are 276 active trials in "Tianjin Medical University Cancer Institute and Hospital". 17 are not yet recruiting, 186 are recruiting, 69 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 78 completed trials in Tianjin Medical University Cancer Institute and Hospital, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Tianjin Medical University Cancer Institute and Hospital, 90 "Phase 1" clinical trials were conducted, 192 "Phase 2" clinical trials and 183 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 30 trials that are defined as “Not Applicable".

Tianjin Medical University Cancer Institute and Hospital has several departments that took part in Clinical trials: "Department of Radiation Oncology, Tianjin Medical University Cancer Hospital" - 6 trials, "Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital" - 4 trials, "Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy" - 2 trials, "Treatment and Diagnosis Center of Leukemia" - 2 trials